Genomics Informatics Market Research Report Segmented By Deployment Mode (On-Premise and Cloud-based); By Technology (Next Generation Sequencing (NGS), Sanger Sequencing, and Microarray); By End User (Pharmaceutical and Biotechnology Companies, Research and Educational Institutes, Hospitals and Clinics, and Others); and Region- Size, Share, Growth Analysis | Forecast (2024 2030)

Genomics Informatics Market Size (2024 – 2030)

The Global Genomics Informatics Market reached a valuation of USD 6.80 billion and is anticipated to attain a market size of USD 16.41 billion by the culmination of 2030. Projected to exhibit a Compound Annual Growth Rate (CAGR) of 13.4% over the forecast period spanning 2024 to 2030.

Genomic informatics encompasses the exploration of extracting biological information from genomic sequences utilizing computer and statistical methodologies. Following the successful conclusion of the Human Genome Project in 2003, substantial data was generated, prompting the initial development of bioinformatics tools. Presently, with advancements in technology such as Next-Generation Sequencing (NGS), Basic Local Alignment Search Tool (BLAST), and other Artificial Intelligence (AI) tools, the market is experiencing significant growth. The ongoing extensive Research and Development (R&D) endeavors, coupled with the integration of technologies and the evolution of personalized medicine, are poised to unlock substantial potential for this market during the forecast period.

Key Market Insights:

In 2022, the National Human Genome Research Institute issued a report projecting that genomics research is expected to yield between 2 and 40 exabytes of data within the next decade.

The National Institutes of Health (NIH) allocated approximately 4.77 billion U.S. dollars for human genome funding in fiscal year 2022.

The error rate in NGS data ranged between 0.1% to 1%, leading to erroneous data interpretation with implications for the research and healthcare sectors. Quality control measures and enhanced sequencing technologies are being incorporated to address this challenge.

Genomics Informatics Market Drivers:

Market progress is propelled by technological advancements.

Throughout the years, research activities have yielded numerous improvements and breakthroughs, expanding human understanding. Databases and software tools have played a pivotal role in enhancing knowledge, with tools such as Next-Generation Sequencing (NGS), BLAST, FASTA, artificial intelligence, machine learning, data analytics, and cloud-based solutions driving the growth rate. These tools have facilitated increased data generation, making data analysis and interpretation more accessible. As the need for effective solutions and data management grows, there is a heightened focus on research activities aimed at developing sophisticated software.

Increased adoption in clinical applications is fostering development.

A rising interest among young professionals in developing treatments for incurable diseases and disorders has fueled crucial clinical research. Personalized and precision medicine, which involves analyzing an individual's genetic makeup to understand genes, sequences, drug targets, and other relevant factors, has been a focal point. The growing number of healthcare applications and professionals has contributed to discoveries, expanding the market.

Genomics Informatics Market Restraints and Challenges:

Data privacy, costs, data integration, and interpretation complexity are key challenges facing the market.

Data security is a major concern due to the sensitive nature of information, posing risks of exploitation and threats through the introduction of harmful pathogens. Cost-related challenges, including installation, maintenance, and software expenses, as well as the need for significant budgets for workforce training, are hindering factors. Integration issues, inconsistency in clinical records and data comprehension, and a limited understanding of sequencing in this relatively new field are additional challenges.

Genomics Informatics Market Opportunities:

Predictive and preventive healthcare present abundant opportunities for the market. Genomics software aids in analyzing gene sequences to detect abnormalities, contributing to the prevention of chronic diseases. Global expansion, facilitated by the exchange of information between regions with distinct lifestyles and environmental conditions, provides opportunities for enhanced interpretations and analyses. Moreover, the application of genomics informatics to drug repurposing, identifying therapeutic areas and target mechanisms, offers potential solutions for diseases. Additionally, Artificial Intelligence (AI) and Machine Learning (ML) contribute valuable insights to development efforts.

Genomics Informatics Market Segmentation: By Deployment Mode

• On-Premise
• Cloud-based

In terms of deployment mode, the cloud-based segment emerges as both the largest and most rapidly expanding sector in the market, commanding a share exceeding 65%. This dominance is attributed to its inherent advantages such as flexibility, cost-effectiveness, availability, scalability, and the backing of major corporations offering this solution. Forecasts for this segment indicate continued substantial growth during the projected period.

Genomics Informatics Market Segmentation: By Technology

• Next Generation Sequencing (NGS)
• Sanger Sequencing
• Microarray

The technology segment highlights next-generation sequencing as the predominant and fastest-growing domain in the market. This trend is driven by ongoing advancements, the availability of sophisticated software tools, clinical applications like drug discovery, genetic screening, and precision medicine, access to extensive data, a robust workforce engaged in research and development, vast potential, and the cost-effectiveness of diagnostic tools. Furthermore, ongoing research on its application in agriculture and ecological settings supports the sustained growth of this segment.

Genomics Informatics Market Segmentation: By End User

• Pharmaceutical and Biotechnology Companies
• Research and Educational Institutes
• Hospitals and Clinics
• Others

Pharmaceutical and biotechnology companies stand out as the primary and largest growing end users, holding a substantial share of approximately 36% in this market. This is attributed to resource availability, funding, an expanded workforce, expertise, access to databases, global reach, collaborations, and strategic partnerships. Meanwhile, research and educational institutions experience the fastest growth, fueled by increased interest among students and researchers, governmental support through initiatives and investments, a rising number of institutions, accessibility to advanced technologies, and support from multinational companies. Educational institutions, in particular, contribute significantly by providing foundational knowledge through laboratory sessions equipped with publicly available tools and databases, securing a total share of around 24%.

Genomics Informatics Market Segmentation: Regional Analysis

• North America
• Asia-Pacific
• Europe
• South America
• Middle East and Africa

In terms of regional analysis, North America emerges as the largest growing market, with countries such as the United States and Canada taking the lead. The region is estimated to capture a share of around 40%, driven by technological advancements, economic strength, prominent research institutes, the presence of key companies, easy access, demand, and substantial investments. Meanwhile, the Asia-Pacific region is identified as the fastest-growing, boasting a share of approximately 20%. Countries like China, India, and Singapore dominate this growth due to renowned research institutions, economic development, emerging markets, increased funding, technological improvements, governmental support, and strategic initiatives.

COVID-19 Impact Analysis on the Global Genomics Informatics Market:

The global genomics informatics market experienced a positive impact from the COVID-19 pandemic. The imperative need for vaccine development led to a heightened focus on genetic sequencing to study defense mechanisms, targets, and other sequencing aspects. This resulted in increased utilization of genetics software and informatics tools for tracking infections and ensuring prevention of further spread. Moreover, genomic tools played a crucial role in assessing vaccine efficacy. Significantly heightened R&D funding for public health, coupled with the adoption of telemedicine during lockdowns and movement restrictions, further bolstered the market. Genomic services were extensively employed for counseling and other purposes, with special initiatives implemented to prevent disruptions in the healthcare supply chain and logistics. Post-pandemic, the market sustained its upward trajectory through continued studies in the field.

Latest Trends/Developments:

Companies in the genomics informatics industry are strategically increasing their market share through alliances, investments, and acquisitions. Maintaining competitive pricing remains a priority, with significant focus on advancing existing technologies and exploring new ones. Notably, the fields of epigenomics and pharmacogenomics are witnessing increased attention for the development of personalized medicine.

Key Players:

1. Illumina, Inc.
2. Thermo Fisher Scientific
3. Qiagen
4. BGI (Beijing Genomics Institute)
5. Pacific Biosciences
6. Seven Bridges
7. DNAnexus
8. Sophia Genetics
9. Broad Institute
10. Bionano Genomics

• In October 2023, Sysmex Group Company, a leading global provider of genomic research and diagnostic solutions, announced a strategic partnership with Intelliseq, a genome informatics company specializing in Next-Generation Sequencing (NGS) analysis solutions. This collaboration integrated OGT's expansive SureSeq™ NGS portfolio with Intelliseq's state-of-the-art iFlow™ engine, resulting in a comprehensive NGS workflow—from sample to report.
• In March 2022, DNAnexus, a cloud-based biomedical data analysis software developer, successfully completed a $200 million financing round aimed at advancing the global adoption of its technology. The funds will be utilized to expedite the development of its core genomics and multi-omics platform, support international growth, and integrate new artificial intelligence (AI) and machine learning technologies and tools.
• In June 2020, Illumina acquired BlueBee, a cloud-based, rapidly configurable omics data analysis platform developer. This strategic move aimed to accelerate Illumina's analysis and sharing of next-generation sequencing (NGS) data at scale.